Navigation Links
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
Date:11/26/2007

ver 20 years in Germany, Austria, Switzerland, and several other countries, where it is licensed under the trade name Berinert(R) P for the treatment of acute HAE attacks.

"The successful completion of this trial confirms longstanding observations made from the administration of more than 300,000 treatments of C1-INH concentrate in Europe. We are delighted that it will now be submitted for registration in the UK," said Dr. Hilary Longhurst, Consultant Immunologist, Barts and The London NHS Trust, London, England, and investigator of the I.M.P.A.C.T. trial.

Study design and results

HAE is caused by the partial absence of functional C1 inhibitor in the blood. The objective of I.M.P.A.C.T. was to assess whether replacing the C1 protein missing in patients with HAE through treatment with C1-INH can address the underlying mechanism of the disease.

I.M.P.A.C.T. evaluated in a prospective and double-blind fashion whether different doses of human pasteurized C1-INH concentrate lead to faster relief of acute symptoms of abdominal and facial attacks compared with placebo in patients with HAE. It is also the largest dose comparison study ever done in HAE. To be eligible for inclusion in the study, patients had to be six years of age or older, with a diagnosis of C1-INH deficiency and a documented history of facial or abdominal attacks.

The primary objective was to show that C1-INH shortens the time to onset of relief of symptoms of abdominal or facial HAE attacks. The primary endpoint was time between start of C1-INH administration and onset of relief of symptoms from abdominal or facial attacks as determined by the subject's assessment. The median time to onset of relief of symptoms in the 20 U/kg b.w. C1-INH treatment group was 30 minutes, compared to 1.5 hours for patients who received placebo.

The secondary endpoint, that is, the proportion of subjects with increased intensity of clinical HAE symptoms between two and four hours aft
'/>"/>

SOURCE CSL Behring
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
5. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
6. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
7. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
8. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
(Date:5/24/2013)... BEIJING , May 24, 2013  Sinovac ... leading provider of biopharmaceutical products in ... main operating subsidiary company of Sinovac, obtained the ... (GMP Certificate) from the China State and Food ... district bulk production plants, and its Changping filing ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... MERCER ISLAND, Wash., Dec. 22, 2010 Renal Advantage and ... the third largest provider of dialysis services in the U.S., ... – terms of which were not disclosed – was completed ... serving more than 19,000 patients in 260 locations in 32 ...
... AstraZeneca (NYSE: AZN ... will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric ... dyslipidemia. This means the co-development and license agreement with Abbott ... Complete Response Letter (CRL) for the CERTRIAD New Drug Application ...
Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:5/25/2013)... 25, 2013 Studies from Johns Hopkins ... carrying excessive weight and their inability to get adequate ... losing weight can naturally relieve many symptoms. , ... in sleep quality was significantly associated with overall weight ... study dated November 6th, 2012, researchers monitored 77 ...
(Date:5/25/2013)... Absolute Surgical Specialists, serving Sun City Center ... businesses throughout the country participating in Shop Local for a ... nationwide event as he understands what military families go through ... He said, “I wanted to give something back, as I ... live here too.” , Shop Local for a Cause has ...
(Date:5/25/2013)... York, New York (PRWEB) May 25, 2013 ... who allegedly suffered serious, life-threatening episodes of internal bleeding while ... litigation underway in U.S. District Court, Southern District of Illinois, ... the Court’s website, 818 Pradaxa side effect claims had ... 2013. That’s up from 705 claims reported by the ...
(Date:5/25/2013)... By working diligently for months on ... of the 2012 Lamborghini Aventador into their well-built fitments ... in the list of vehicles lined by SizeItUp for ... set to thrill automobile lovers in the year 2013. ... looks, the 2012 Lamborghini Aventador comes with extraordinarily spacious ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 According ... Emergency Management Market, 2013–2018", published by MarketsandMarkets is ... a CARC of 5.54% which analyzes and studies ... North America, Europe, Asia, and Rest of the ... Market Data Tables , 87 Figures ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4
... Garca Navarro, a researcher at the School of Pharmacy at ... colon and liver cancer. The new treatment has shown ... ,This discovery is the principal result of her doctoral ... Cancer Cells of the Colon, which was subsidized by the ...
... who suffer bouts of nausea and vomiting during their pregnancies ... but it seems that going through morning sickness is a ... who have conducted a new study and found that women ... risk of developing breast cancer later in life than expecting ...
... shown a decline, thanks to the comprehensive program in 2002, ... 2006 report shows a decline in the smoking rate ... past year, smoking decreased among men (from 22.5% to 19.9%) ... followed a year-long ad campaign aimed at prompting more smokers ...
... cause effects ranging from learning and memory capabilities to ... of St.Jude Childrens Research hospital . ... factora molecule that binds to a section of DNA near ... protein for which it codes. CREB activates genes in response ...
... who allegedly tried to get his 15-year-old son into the record ... said the accusation was a ploy by his detractors to defame ... a video recording of his son Dhileepan Raj, a tenth standard ... other doctors in the hope of making his son attain the ...
... occurs as a solid tumor in the abdomen, but ... the network of the body's sympathetic nervous system. ... neuroblastoma is a special case, accounting for 7 percent ... cancer deaths. ,Neuroblastoma is what physicians ...
Cached Medicine News:Health News:Novel Treatment Beneficial for Colon and Liver Cancer 2Health News:Morning Sickness may Signify Lower Breast Cancer Risk 2Health News:Morning Sickness may Signify Lower Breast Cancer Risk 3Health News:New York Records Decline in Smoking Rate 2Health News:Research Studies on Molecular Switches of Gene 2Health News:The Bottleneck in Neuroblastoma 2
... BioControl multichannel has the ... the single channel model.The ... all seven multichannel and ... cone modules. Both pipettes ...
... in a wide variety of applications. • Whole ... can be freely rotated against the handle to ... an optimum angle towards the microtiter plate. • ... of most common pipette tips, and provides a ...
... value!, Comfortable feel and less hand ... Finer control while pipetting with smooth, light ... with long, lever tip ejector , Completely ... the need for recalibration , Easy-to-read precision ...
... Designed with 96-well plates in ... useful for molecular biology applications: PCR* ... 96-well plates, etc. Used with Diamond ... system, this product will maximize performance ...
Medicine Products: